Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 28Active not recruiting 20Not yet recruiting 4Suspended 2Withdrawn 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1

Interventions

Specimen Handling 21Biopsy 14Magnetic Resonance Spectroscopy 13Cyclophosphamide 4Nivolumab 3Cetuximab 3Azacitidine 3venetoclax 2trastuzumab deruxtecan 2decitabine and cedazuridine drug combination 2X-Rays 2Vincristine 2Taxes 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Prednisone 2Practice Guidelines as Topic 2Lenalidomide 2Ipilimumab 2Etoposide 2Doxorubicin 2CTLA-4 Antigen 2(225)Ac-DOTA-c(RGDyK) 2spartalizumab 1relatlimab 1prednylidene 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × X-Rays × 30 days × Clear all
NCT04539366 2026-05-13

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

National Cancer Institute (NCI)

Phase 1 Suspended
67 enrolled
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

National Cancer Institute (NCI)

Phase 1 Suspended
66 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡